Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Lung cancer patients with comorbid conditions face higher risk of death

Lung cancer patients with comorbid conditions such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure had a higher risk of death than lung cancer patients without comorbid conditions, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

12 Jun 2015

Findings point to new therapy against prostate and other cancers

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found that a drug candidate with anticancer potential can be activated by one of the body's natural responses to cellular stress. Once activated, the agent can kill prostate cancer cells.

11 Jun 2015

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan.

10 Jun 2015

New study shows that estrogen receptors vanish in cervical cancer tumors

Scientists have prior evidence that the hormone estrogen is a major driver in the growth of cervical cancer, but a new study examining genetic profiles of 128 clinical cases reached a surprising conclusion: Estrogen receptors all but vanish in cervical cancer tumors.

10 Jun 2015

Pathology expert shares vital information about prostate cancer

Requesting a copy of your pathology report, asking questions of your doctor and playing an active role in decision-making are important ways that men should take control of their health.

10 Jun 2015

Findings underscore the value of emotional, informational support for prostate cancer patients

A study led by the University at Buffalo and Roswell Park Cancer Institute has identified beliefs and personality traits that are associated with higher levels of distress in newly diagnosed prostate cancer patients.

10 Jun 2015

QUT cancer and eye researchers named in Queen's Birthday honours

Professor Clements is honoured for her outstanding contribution to biomedical research, particularly prostate cancer research, and for her success in generating ongoing funding to support the establishment of critically-needed national medical research facilities.

10 Jun 2015

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.

9 Jun 2015

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.

7 Jun 2015

Researchers identify immune system marker that drives therapy-resistant prostate cancer

You are a patient who has just been treated for a serious illness but neither you nor your doctor knows how likely it is that you -- in comparison with other patients -- will actually be helped by the treatment. This is often the situation with prostate cancer, one of the deadliest and most highly prevalent cancers. While hormone therapy can help, patient responses vary widely, and it's still unclear why some types of prostate cancer seem to be resistant to the therapy.

5 Jun 2015

Medical experts call for accurate, standardized estrogen testing methods

Unreliable estrogen measurements have had a negative impact on the treatment of and research into many hormone-related cancers and chronic conditions. To improve patient care, a panel of medical experts has called for accurate, standardized estrogen testing methods in a statement published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Jun 2015

Survey shows most men with advanced prostate cancer ignore their symptoms as disease progresses

Prostate cancer is the second most common cancer and the second leading cause of cancer-related deaths among men in the U.S...

3 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors.

2 Jun 2015

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).

2 Jun 2015

Philips to highlight range of Magnetic Resonance solutions at 23rd ISMRM

Royal Philips today announced the range of its Magnetic Resonance (MR) solutions to be showcased at the International Society for Magnetic Resonance in Medicine's (ISMRM) 23rd Annual Meeting & Exhibition in Toronto, Canada.

2 Jun 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.

2 Jun 2015

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

2 Jun 2015

Heart-healthy diet may benefit men after prostate cancer diagnosis

After a prostate cancer diagnosis, eating a diet higher in red and processed meat, high-fat dairy foods, and refined grains--known as a Western diet--may lead to a significantly higher risk of both prostate cancer-related mortality and overall mortality compared with eating a diet rich in vegetables, fruits, fish, whole grains, and healthy oils, according to a new study from Harvard T.H. Chan School of Public Health.

1 Jun 2015

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.

1 Jun 2015

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Lung cancer patients with comorbid conditions face higher risk of death

Findings point to new therapy against prostate and other cancers

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

New study shows that estrogen receptors vanish in cervical cancer tumors

Pathology expert shares vital information about prostate cancer

Findings underscore the value of emotional, informational support for prostate cancer patients

QUT cancer and eye researchers named in Queen's Birthday honours

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Researchers identify immune system marker that drives therapy-resistant prostate cancer

Medical experts call for accurate, standardized estrogen testing methods

Survey shows most men with advanced prostate cancer ignore their symptoms as disease progresses

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

Philips to highlight range of Magnetic Resonance solutions at 23rd ISMRM

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Heart-healthy diet may benefit men after prostate cancer diagnosis

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

What to know about prostate cancer eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in